Brought to you by 
Roche and Foundation Medicine form R&D, commercial collaboration
01 Feb 2023
Executive Summary
Concurrent with receiving over $1bn in exchange for its majority stake, Foundation Medicine Inc. (FMI) signed a broad five-year R&D agreement with Roche focused on molecular information and genomic analysis products for cancer.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Immuno-Oncology
-
Drug Discovery Technologies
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche and Foundation Medicine form R&D, commercial collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice